Compare Incyte Corporation (INCY) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Quantum Computing Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Quantum Computing Inc trades at $7.44 (market cap $1.69B). The key difference: Incyte Corporation is far larger — about 13.5× Quantum Computing Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Quantum Computing Inc for 25 Days on average.
| INCY | QUBT | |
|---|---|---|
Market Cap | $22.85B | $1.69B |
Volume | 1,927,029 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $129.93 | $21.78 |
52-Week Low | $83.80 | $6.31 |
Typical Hold Time | 33 Days | 25 Days |
Enterprise Value | $18.35B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
QUBT trades at $7.45, down 2.23% on the day, amid a bearish technical signal from moving averages but with oscillators suggesting potential short-term bullish momentum. The company is in a pre-profitability growth phase, with revenue projected to jump to $10 million in 2026 from $682,000 in 2025, though net losses remain substantial. Recent news highlights the launch of the Dirac-3S quantum system and a $42.5 million backlog, indicating commercial progress but ongoing execution risks.
The investment case hinges on QUBT's ability to scale its quantum computing technology and convert its backlog into sustainable revenue, with a consensus analyst price target of $17.33 implying significant upside. Key risks include persistent cash burn, intense competition, and the speculative nature of the quantum computing sector, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
